Stock News

Chicago Bridge & Iron Co N V (CBI) Valuation Declined While Buckhead Capital Management Upped by $960,000 Its Position; Kerrisdale Advisers Has Lowered Stake in Cara Therapeutics (CARA) by $466,427 as Valuation Rose

Sahm Adrangi decreased its stake in Cara Therapeutics Inc (CARA) by 71.76% based on its latest 2017Q3 regulatory filing with the SEC. Kerrisdale Advisers Llc sold 35,879 shares as the company’s stock rose 14.02% with the market. The hedge fund run by Sahm Adrangi held 14,121 shares of the health care company at the end of 2017Q3, valued at $193,000, down from 50,000 at the end of the previous reported quarter. Kerrisdale Advisers Llc who had been investing in Cara Therapeutics Inc for a number of months, seems to be less bullish one the $472.17 million market cap company. The stock decreased 2.43% or $0.36 during the last trading session, reaching $14.48. About 767,150 shares traded. Cara Therapeutics, Inc. (NASDAQ:CARA) has risen 206.00% since February 17, 2017 and is uptrending. It has outperformed by 189.30% the S&P500.

Buckhead Capital Management Llc increased its stake in Chicago Bridge & Iron Co N V (CBI) by 33.33% based on its latest 2017Q3 regulatory filing with the SEC. Buckhead Capital Management Llc bought 60,000 shares as the company’s stock declined 38.73% while stock markets rallied. The hedge fund held 240,000 shares of the engineering & construction company at the end of 2017Q3, valued at $4.03M, up from 180,000 at the end of the previous reported quarter. Buckhead Capital Management Llc who had been investing in Chicago Bridge & Iron Co N V for a number of months, seems to be bullish on the $1.90 billion market cap company. The stock increased 0.21% or $0.04 during the last trading session, reaching $18.71. About 1.15M shares traded. Chicago Bridge & Iron Company N.V. (NYSE:CBI) has declined 42.76% since February 17, 2017 and is downtrending. It has underperformed by 59.46% the S&P500.

Buckhead Capital Management Llc, which manages about $1.27 billion and $465.09 million US Long portfolio, decreased its stake in Jpmorgan Chase & Co (NYSE:JPM) by 42,425 shares to 112,395 shares, valued at $10.74M in 2017Q3, according to the filing. It also reduced its holding in National Oilwell Varco Inc (NYSE:NOV) by 41,803 shares in the quarter, leaving it with 34,297 shares, and cut its stake in Target Corp (NYSE:TGT).

Among 17 analysts covering Chicago Bridge & Iron Company (NYSE:CBI), 6 have Buy rating, 1 Sell and 10 Hold. Therefore 35% are positive. Chicago Bridge & Iron Company had 50 analyst reports since August 14, 2015 according to SRatingsIntel. Citigroup initiated Chicago Bridge & Iron Company N.V. (NYSE:CBI) on Friday, November 13 with “Buy” rating. KeyBanc Capital Markets maintained the shares of CBI in report on Tuesday, September 19 with “Hold” rating. Tudor Pickering upgraded Chicago Bridge & Iron Company N.V. (NYSE:CBI) on Wednesday, October 28 to “Buy” rating. The stock has “Hold” rating by Robert W. Baird on Friday, September 15. On Wednesday, August 16 the stock rating was downgraded by Jefferies to “Hold”. On Wednesday, November 1 the stock rating was maintained by UBS with “Neutral”. The firm has “Hold” rating by Jefferies given on Tuesday, October 31. The firm earned “Hold” rating on Friday, October 20 by Robert W. Baird. Deutsche Bank maintained the stock with “Buy” rating in Tuesday, October 24 report. Macquarie Research upgraded the stock to “Hold” rating in Tuesday, December 19 report.

Since September 20, 2017, it had 0 insider purchases, and 3 sales for $363,000 activity.

Investors sentiment decreased to 0.72 in Q3 2017. Its down 0.18, from 0.9 in 2017Q2. It worsened, as 71 investors sold CBI shares while 83 reduced holdings. 49 funds opened positions while 62 raised stakes. 66.18 million shares or 0.62% less from 66.59 million shares in 2017Q2 were reported. Hap Trading Ltd Liability Corp holds 0.05% or 61,537 shares. Lpl Finance Lc invested in 73,098 shares. Whittier reported 3 shares. Legal General Grp Public has 0% invested in Chicago Bridge & Iron Company N.V. (NYSE:CBI). Moreover, First Manhattan has 0% invested in Chicago Bridge & Iron Company N.V. (NYSE:CBI). Griffin Asset Management accumulated 14,650 shares or 0.04% of the stock. Creative Planning holds 23,485 shares or 0% of its portfolio. Illinois-based Northern Corp has invested 0.01% in Chicago Bridge & Iron Company N.V. (NYSE:CBI). Fairpointe Limited Co reported 5.04 million shares. Whittier Of Nevada owns 360 shares. Arcadia Invest Mngmt Mi has invested 0.05% in Chicago Bridge & Iron Company N.V. (NYSE:CBI). New York-based Eii Capital Mngmt Incorporated has invested 0.42% in Chicago Bridge & Iron Company N.V. (NYSE:CBI). Huntington Bankshares has invested 0% in Chicago Bridge & Iron Company N.V. (NYSE:CBI). Blackrock Incorporated stated it has 0.01% in Chicago Bridge & Iron Company N.V. (NYSE:CBI). 21,179 were accumulated by Raymond James Financial Ser Advsr.

Since January 24, 2018, it had 0 insider purchases, and 2 sales for $412,500 activity. $225,000 worth of Cara Therapeutics, Inc. (NASDAQ:CARA) was sold by Menzaghi Frederique Ph.D..

Kerrisdale Advisers Llc, which manages about $371.12 million and $95.80 million US Long portfolio, upped its stake in Luxoft Hldg Inc (NYSE:LXFT) by 459,033 shares to 765,514 shares, valued at $36.59 million in 2017Q3, according to the filing.

Among 10 analysts covering Cara Therapeutics (NASDAQ:CARA), 10 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cara Therapeutics had 24 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, August 4 by H.C. Wainwright. The firm has “Buy” rating by Needham given on Wednesday, June 21. The firm has “Buy” rating by Needham given on Tuesday, October 3. The firm has “Buy” rating by Piper Jaffray given on Friday, August 4. The company was initiated on Thursday, October 13 by H.C. Wainwright. As per Thursday, June 22, the company rating was maintained by H.C. Wainwright. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, August 3 report. The stock of Cara Therapeutics, Inc. (NASDAQ:CARA) has “Buy” rating given on Thursday, July 13 by H.C. Wainwright. The rating was maintained by Stifel Nicolaus with “Buy” on Tuesday, January 2. Laidlaw maintained it with “Buy” rating and $3000 target in Friday, June 30 report.

Analysts await Cara Therapeutics, Inc. (NASDAQ:CARA) to report earnings on March, 8. They expect $-0.39 EPS, up 51.85% or $0.42 from last year’s $-0.81 per share. After $-0.38 actual EPS reported by Cara Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 2.63% negative EPS growth.

Investors sentiment decreased to 0.85 in 2017 Q3. Its down 0.76, from 1.61 in 2017Q2. It worsened, as 22 investors sold CARA shares while 31 reduced holdings. 20 funds opened positions while 25 raised stakes. 17.83 million shares or 4.68% less from 18.71 million shares in 2017Q2 were reported. Credit Suisse Ag holds 0% or 50,084 shares in its portfolio. C Ww Grp Incorporated Hldg A S has 0.06% invested in Cara Therapeutics, Inc. (NASDAQ:CARA) for 291,341 shares. California Employees Retirement Systems holds 166,273 shares. Wells Fargo & Mn holds 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA) for 28,124 shares. Ameritas Partners holds 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA) for 2,345 shares. Bancorporation Of Ny Mellon holds 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA) for 121,307 shares. Vantage Investment Advsrs Ltd holds 0.01% or 1,700 shares in its portfolio. Sg Americas Secs Limited Liability Com reported 25,353 shares. Oz Management Ltd Partnership owns 35,000 shares. 1.18 million are owned by Vanguard Grp. State Of Wisconsin Invest Board accumulated 20,000 shares or 0% of the stock. Quantbot Tech Lp reported 0% of its portfolio in Cara Therapeutics, Inc. (NASDAQ:CARA). Disciplined Growth Mn stated it has 849,150 shares. Price T Rowe Associates Md holds 0% or 456,253 shares in its portfolio. Next Fin Grp Incorporated Inc holds 40 shares or 0% of its portfolio.

Leave a Reply

Your email address will not be published. Required fields are marked *